As we stated earlier, muscular dystrophy affects muscles, but not just the skeletal muscles, or those used for walking and arm strength. It also involves heart muscles and those used for breathing. When people use a wheelchair they can get a curve of the spine which can require spinal surgery. MD is genetic so people need genetic counselling and testing facilities. They may also require speech and language therapy and psychological services. In some cases there can be learning difficulties. Although they might be mild they still require some form of intervention.
People might need aids and appliances, along with adaptation of their homes and social welfare entitlements. They must negotiate their way through a significant range of different Departments and services. These people need a co-ordinated approach to care.
In order to manage the condition, multidisciplinary teams seem to be the best approach. MDI is working closely with health care professionals to ensure members needs are met to the highest possible standard. We have a clinic co-ordinator who attends to two clinics, one for children in the Central Remedial Clinic, CRC, in Dublin and one for adults in Beaumont Hospital. The clinic co-ordinator attends to provide support to families, as travelling from the country to Dublin to attend the clinics can be quite stressful. One does not really know what will be said on the day. A person might be told the condition has deteriorated and it is important to have somebody there as a support.
We had a conference on advances in the care of Duchenne muscular dystrophy in March this year, organised in conjunction with Dr. Bryan Lynch, the paediatric neurologist from Temple Street and the CRC. It was supported by some of Ireland's leading specialists in the treatment of muscular dystrophy in the areas of neurology, physiotherapy, orthopaedics, respiratory and cardiac care. Those specialists gave their time to talk to families on a Sunday — mother's day as it turned out — so there is a desire on the part of that community to give the highest standard of care to people with muscular dystrophy.
There are some barriers to this objective. The CRC clinic is running well and there is a multidisciplinary team there. It does mean people have to travel from around the country to get to it but once they get there the facilities are good. The problem is mainly with the adult clinic in Beaumont Hospital. The neurologist there works almost on his own so if people come from the country the appointment lasts perhaps ten or 15 minutes. They may be called back again for a respiratory or cardiac appointment.
Dr. Walsh from Beaumont Hospital has indicated his service would be improved by having a multidisciplinary team working around him, including a physiotherapist, occupational therapist, social worker, genetic counsellor and possibly a neuromuscular specialist nurse. Such a team would enable him to provide the best standard of care for members.
People with muscular dystrophy are living longer and therefore there are more children moving from children's services into adult services. As they get to the adult clinic, however, their condition is deteriorating but they find that the standard of service they are getting is not as good as that available when they were children. That is a problem we would like to examine. We want the adult service to be at least as good as the service children are getting in the Central Remedial Clinic.
We must ensure also that between clinic visits the community services — physiotherapy and occupational therapy — are available in local areas. I am aware that some members of MDI are having difficulty accessing those services, particularly in Wexford and the north east where people are having difficulty getting occupational therapy services.
Because muscular dystrophy is a genetic condition the people affected need genetic testing and counselling. That is done through the National Centre for Medical Genetics. That centre is still not funded to provide a nationwide genetic testing service and is working with four consultants to cover 4 million people in Ireland, whereas Belfast has six consultants for the 1.5 million to 2 million people living in Northern Ireland. That means the centre is stretched to a greater degree and there are longer waiting lists for some of our families to access testing and counselling. Testing is important because there are different types of muscular dystrophy. People need to know the type they have to understand if there is a chance of any other members of their family being affected or if they have to make decisions as to whether to have children.
Currently there is no cure and no definitive treatment for any form of muscular dystrophy. Getting access to these services, particularly cardiac and respiratory monitoring and treatment, was shown to increase life expectancy in boys with Duchenne muscular dystrophy by over ten years between the 1960s and the 1990s in the Newcastle region in England. That was because of access to assisted ventilation, which can help with one's breathing, and to cardiac treatment. It is essential that everybody gets access to those specialties.
Research into MD is progressing and clinical trials have begun. When I started working with Muscular Dystrophy Ireland five years ago, such trials were considered so far off that people did not think about them. Clinical trials have now started in the United Kingdom. The EMDEX consortium is examining exon skipping as a potential therapy for Duchenne muscular dystrophy, with the possibility of it being used for other forms of muscular dystrophy if successful.
The research is progressing well. It is hoped EMDEX will move to the next phase of the trial at the end of this year. A number of Irish families are heavily involved in fund-raising to try to ensure that this research progresses to its conclusion. It is currently funded only to the end of the next phase of the trail but a number of other phases of the study will be needed after that.
Boys from Ireland are now eligible to go to England to participate in the clinical trial. That is something that happened recently and we would be optimistic about it but we must plan for the future. Ireland does not have a strong clinical research tradition but it is becoming more important. These issues are becoming more of a reality. Beaumont Hospital and the CRC are asking for research nurses to co-ordinate involvement in any future clinical trials.
In the event of genetic treatment ever becoming available, people will need to know the precise genetic mutation they have. Therefore, we might have far more families contacting the Centre for Medical Genetics to know the form of genetic mutation they have and whether there are any treatments that would benefit them. We might anticipate that in the future there would be further pressure on an already stretched genetic service. I will hand over to Ms Brill who will speak about living with the condition.